Effects of Early Use of Nitazoxanide in Patients With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

392

Participants

Timeline

Start Date

June 8, 2020

Primary Completion Date

August 20, 2020

Study Completion Date

September 5, 2020

Conditions
Covid19Coronavirus
Interventions
DRUG

Nitazoxanide

Nitazoxanide 500mg 8/8 hours for 5 days in the early clinical phase of COVID-19.

DRUG

Placebo

Placebo 8/8 hours for 5 days in the early clinical phase of COVID-19.

Trial Locations (1)

21941902

Universidade Federal do Rio de Janeiro, Rio de Janeiro

All Listed Sponsors
collaborator

Ministry of Science and Technology, Brazil

OTHER

collaborator

National Research Council, Brazil

OTHER

collaborator

ATCGen

UNKNOWN

collaborator

Complexo Hospitalar Municipal de São Caetano do Sul

UNKNOWN

collaborator

Hospital de Transplante Doutor Euryclides de Jesus Zerbini

OTHER

collaborator

Secretaria Municipal de Saúde de Bauru

UNKNOWN

collaborator

Santa Casa de Misericórdia de Sorocaba

UNKNOWN

collaborator

Secretaria Municipal de Saúde de Guarulhos

UNKNOWN

collaborator

Hospital e Maternidade Therezinha de Jesus

UNKNOWN

collaborator

Secretaria de Estado de Saúde do Distrito Federal

UNKNOWN

lead

Universidade Federal do Rio de Janeiro

OTHER

NCT04552483 - Effects of Early Use of Nitazoxanide in Patients With COVID-19 | Biotech Hunter | Biotech Hunter